Last reviewed · How we verify
Single Ascending Dose of SAB-176 — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Single Ascending Dose of SAB-176 (Single Ascending Dose of SAB-176) — SAb Biotherapeutics, Inc..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Single Ascending Dose of SAB-176 TARGET | Single Ascending Dose of SAB-176 | SAb Biotherapeutics, Inc. | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Single Ascending Dose of SAB-176 CI watch — RSS
- Single Ascending Dose of SAB-176 CI watch — Atom
- Single Ascending Dose of SAB-176 CI watch — JSON
- Single Ascending Dose of SAB-176 alone — RSS
Cite this brief
Drug Landscape (2026). Single Ascending Dose of SAB-176 — Competitive Intelligence Brief. https://druglandscape.com/ci/single-ascending-dose-of-sab-176. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab